SEHK:9926Biotechs
Akeso (SEHK:9926) Stock Could Be 49% Undervalued After New AML Trial Data
Akeso (SEHK:9926) is back in focus after presenting Phase II data for its anti CD47 antibody ligufalimab in acute myeloid leukemia at the 2026 European Hematology Association Congress, highlighting survival and response outcomes versus standard therapy.
See our latest analysis for Akeso.
Akeso's HK$87.55 share price has seen a 4.35% 1 day gain but is still down 22.38% over 30 days and 24.26% over 90 days. The 3 year total shareholder return of 152.67% contrasts with a 4.89% decline over the...